Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Psoriatic arthritis (PsA), a chronic inflammatory condition characterized by dactylitis, enthesitis, peripheral arthritis, skin and nail psoriasis, and spondylitis, occurs in around 10%-30% of people ...

Anyone can develop psoriatic arthritis, but it’s most common in people who already have psoriasis, affecting about 30 percent of people with the skin condition. Whether you’re managing just psoriatic ...

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of developing psoriatic arthritis, an inflammatory condition that impacts the ...

When the immune system mistakenly attacks healthy cells in both the skin and joints, the result is psoriatic arthritis—a challenging condition that affects approximately 1 million Americans. While ...

Psoriatic arthritis is a chronic inflammatory condition that can significantly impact the quality of life of those affected. Understanding where and how this disease manifests in the body can help in ...

There was a point a few years ago that Chef Michelle Bernstein thought her livelihood was finished. The James Beard Award-winning chef, who has appeared on cooking competitions like Top Chef and ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

Joni Kazantzis was diagnosed with psoriasis at 15 and received a psoriatic arthritis diagnosis during the pandemic. She created a blog and social platform to offer the guidance she once ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

At week 16, both trials showed a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response compared with placebo. Topline data were announced from two phase 3 trials ...

The Global Healthy Living Foundation (GHLF) is excited to present innovative and transformative research at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This marks ...